Skip to main content
KTTA
NASDAQ Life Sciences

Pasithea to Unveil First PAS-004 NF1 Clinical Data at European Conference

Tom Rudovsky · Reported by GlobeNewswire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$0.55
Mkt Cap
$17.71M
52W Low
$0.281
52W High
$2.06
52W Position info
96% above low
Off High info
73% below high
Rel. Volume info
0.2× avg
Market data snapshot near publication time

KTTA sits 96% above its 52-week low of $0.281 on light trading volume (0.2× avg).

Summary

Pasithea will present initial Part A data from its Phase 1/1b trial of PAS-004 in adult NF1 patients at the European Neurofibromatosis Conference in Vienna, November 12-14. This is the first public disclosure of clinical data from this trial, with an oral presentation on cutaneous neurofibromas and a poster on plexiform neurofibromas. The company plans to issue a detailed results press release at the time of presentation. This follows positive interim Phase 1 data in advanced cancer patients reported in June, and the recent shareholder approval of a reverse stock split to address Nasdaq listing requirements. The upcoming data could validate PAS-004's potential in NF1, a significant unmet need, and may influence the company's financing and partnership prospects.

At the time of this announcement, KTTA was trading at $0.55 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $17.7M. The 52-week trading range was $0.28 to $2.06. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.


Price Chart

Share this article

Copied!

KTTA - Latest Insights

KTTA
Nov 17, 2026, 8:42 PM EST
Filing Type: 4
Importance Score:
8
Price at Filing: $0.4343
Real-time Price: $0.4417 info
Change: +$0.0074 (+2%) info
Market Cap: $15.962M info
KTTA
Nov 13, 2026, 5:17 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $0.479
Real-time Price: $0.4417 info
Change: -$0.0373 (-8%) info
Market Cap: $15.962M info
KTTA
Nov 13, 2026, 2:00 AM EST
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $0.510
Real-time Price: $0.4417 info
Change: -$0.0683 (-13%) info
Market Cap: $15.962M info
KTTA
Nov 03, 2026, 7:00 AM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $0.3591
Real-time Price: $0.4417 info
Change: +$0.0826 (+23%) info
Market Cap: $15.962M info
KTTA
Sep 09, 2026, 4:20 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.5697
Real-time Price: $0.4417 info
Change: -$0.128 (-22%) info
Market Cap: $15.962M info